Status:
COMPLETED
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
Lead Sponsor:
Daiichi Sankyo
Conditions:
Gastric Cancer
Gastroesophageal Junction Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study will be conducted to retrospectively evaluate the treatment patterns in first-line, second-line, and subsequent lines of therapy for HER2-positive Gastric Cancer/Gastroesophageal Junction C...
Detailed Description
This is a multicenter, non-interventional, retrospective real-world study to analyze the treatment patterns for patients with GC/GEJC in the first-line, second-line, and subsequent lines of treatment....
Eligibility Criteria
Inclusion
- Inclusion criteria
- Patients with pathologically diagnosed locally advanced unresectable or metastatic GC/GEJC (limited to those diagnosed since October 1, 2017) and initiating first-line treatment between January 1, 2018, and March 31, 2023
- Patients aged ≥ 18 years at the time of diagnosis with locally advanced unresectable or metastatic GC/GEJC; HER2-positive status2, determined by either tissue samples from the first biopsy or liquid biopsy samples (if a patient has both tissue and liquid biopsy samples, tissue samples will be the standard).
- Exclusion criteria
- Patients with other primary malignant tumors
- Patients enrolled in clinical trials and receiving active anti-cancer therapy after July.1, 2017 (excluding retrospective studies).
- Patients with critical missing data in medical records or otherwise deemed for inclusion by the investigator
Exclusion
Key Trial Info
Start Date :
August 15 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2025
Estimated Enrollment :
805 Patients enrolled
Trial Details
Trial ID
NCT06585501
Start Date
August 15 2024
End Date
July 30 2025
Last Update
August 21 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, China
2
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
3
Zhejiang Provincial People's Hospital
Hangzhou, China
4
Harbin Medical University Cancer Hospital
Harbin, China